课题基金 / 基金详情

项目摘要

项目成果

DAVID H LOVETT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Interstitial fibrosis and tubular atrophy are the hallmarks of all forms of progressive renal fibrosis. This laboratory has focused over the past decade on the role of specific matrix metalloproteinases (MMP-2 and MT1-MMP) in this process. MMP-2, in conjuction with MT1-MMP, is sufficient to induce the conversion of the polarized epithelial cell to a fibroblastic phenotype, a processtermed epithelial mesenchymal transition (EMT). Quantitatively, EMT, in conjunction with activation and expansion of the interstitial fibroblast population, is a major contributor to tubular atrophy and progressiverenal fibrosis. In vitro, EMT is driven by a diverse number of cytokines and environmental factors; however, we have postulated that renal EMT represents a metastable state driven by three dominant transcriptional networks: TGF-beta/Smad; E- cadherin/beta-catenin/Wnt/LEF/TCF; and MAPK/ERKsignaling cascades. We have identified both MMP-2 and MT1-MMP as transcriptional targets of the MAPK/ERKsignaling cascades and determined that a specific AP-1 complex component, Fra-2, is sufficient to drive the process of EMT in vitro. The primary hypothesis of this proposal is that sustained MAPK/ERK signaling, with enhanced generation of Fra-2, drives the transcription of a defined cohort of genes required for renal EMT. The approaches to this problem include three Specific Aims proposing to characterize, using microarray analysis, Fra-2-regulated genes in a series of clonal populations of epithelial cells displaying a range of epithelial to mesenchymal features. The functional significance of identified genes will be validated using in vitro and in vivo approaches, including a unique model of renal EMT generated by the transgenic expressionof active MMP-2 in the renal proximal tubule. Finally, the ability of Fra-2, alone, to induce EMT in vivo will be tested by the transgenic proximal tubule expression of this transcription factor. These studies are designed to identify those gene sets required for renal EMT and thereby hopefully provide new therapeutic targetsfor the treatment of renal disease.
期刊论文(44)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/s12882-018-1029-8
发表时间: 2018-09-25
期刊: BMC nephrology
影响因子: 2.3
作者: [Kim IY, Kim SS, Lee HW, Bae SS, Ha HK, Jung ES, Lee MY, Han M, Rhee H, Seong EY, Lee DW, Lee SB, Lovett DH, Song SH]
通讯作者: Song SH
Two Distinct Isoforms of Matrix Metalloproteinase-2 Are Associated with Human Delayed Kidney Graft Function.
基质金属蛋白酶-2的两个不同的同工型与人类延迟的肾移植功能有关。
DOI: 10.1371/journal.pone.0136276
发表时间: 2015
期刊: PloS one
影响因子: 3.7
作者: [Wanga S, Ceron CS, Delgado C, Joshi SK, Spaulding K, Walker JP, Song S, Olson JL, Lovett DH]
通讯作者: Lovett DH
Human mesangial cells secrete a GBM-degrading neutral proteinase and a specific inhibitor.
人类肾小球系膜细胞分泌GBM降解中性蛋白酶和特异性抑制剂。
DOI: 10.1038/ki.1989.264
发表时间: 1989
期刊: Kidney international
影响因子: 19.6
作者: [Martin,J, Davies,M, Thomas,G, Lovett,DH]
通讯作者: Lovett,DH
Asymmetric origins of the mature glomerular basement membrane.
成熟肾小球基底膜的不对称起源。
DOI: 10.1002/jcp.1041570122
发表时间: 1993
期刊: Journal of cellular physiology
影响因子: 5.6
作者: [Lee,LK, Pollock,AS, Lovett,DH]
通讯作者: Lovett,DH
15
    Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
    Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
    Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
    Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
    国内基金
    海外基金
    多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      郑巧
    • 依托单位:
    Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      52万元
    • 批准年份:
      2022
    • 负责人:
      陈立达
    • 依托单位: